Journal article 500 views 121 downloads
In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection
Antimicrobial Agents and Chemotherapy, Volume: 61, Issue: 5, Start page: e02280-16
-
PDF | Version of Record
This is an open access article distributed under the terms of the Creative Commons CC-BY Attribution License.
Download (845.81KB)
DOI (Published version): 10.1128/AAC.02280-16
Abstract
The profile of PC945, a novel triazole antifungal, designed for administration via inhalation, hasbeen assessed in a range of in vitro and in vivo studies. PC945 was characterized as a potent, tight-binding inhibitor of Aspergillus fumigatus sterol 14α-demethylase (CYP51A and CYP51B)activity.In addi...
| Published in: | Antimicrobial Agents and Chemotherapy |
|---|---|
| ISSN: | 0066-4804 1098-6596 |
| Published: |
2017
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa34336 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
The profile of PC945, a novel triazole antifungal, designed for administration via inhalation, hasbeen assessed in a range of in vitro and in vivo studies. PC945 was characterized as a potent, tight-binding inhibitor of Aspergillus fumigatus sterol 14α-demethylase (CYP51A and CYP51B)activity.In addition, when A. fumigatus hyphae or human bronchial cells were treated with PC945, and thenwashed, PC945 was found to be quickly absorbed into both target and non-target cells and toproduce persistent antifungal effects. In temporarily neutropenic immunocompromised miceinfected with A. fumigatus intranasally, 50% of the animals survived until day 7 when treatedintranasally with PC945 at 0.56 μg/mouse, while posaconazole showed similar effects (44%) at14 μg/mouse. This profile affirms that topical treatment with PC945 should provide potentantifungal activity in the lung. |
|---|---|
| College: |
Swansea University Medical School |
| Issue: |
5 |
| Start Page: |
e02280-16 |